EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Synthetic Biology Facilitates Semisynthetic Development of Type V Glycopeptide Antibiotics Targeting Vancomycin-Resistant Enterococcus

Kalinka Koteva, Min Xu, Wenliang Wang, Aline A Fiebig-Comyn, Michael A Cook iD, Brian K Coombes, Gerard D Wright iD

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c00633 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Kalinka Koteva und 6 weiteren Autor:innen. Beteiligte Einrichtung: David Braley Centre for Antibiotic Discovery, M.G. DeGroote Institute for Infectious Disease Research, Department of Biochemistry and Biomedical Scie…. Hauptthemen laut MEDLINE: Gram-Positive Bacterial Infections, Vancomycin-Resistant Enterococci. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The continued efficacy of glycopeptide antibiotics (GPAs) against Gram-positive bacteria is challenged by the emergence and spread of GPA-resistant pathogens, particularly vancomycin-resistant enterococci (VRE). The growing frequency of GPA resistance propels the need for innovative development of more effective antibiotics. Unlike canonical GPAs like vancomycin, Type V GPAs adopt a distinct mode of action by binding peptidoglycan and blocking the activity of autolysins essential for cell division, rendering them a promising class of antibiotics for further development. In this study, the Type V GPA, rimomycin A, was modified to generate 32 new analogues. Compound 17, derived from rimomycin A through N-terminal acylation and C-terminal amidation, exhibited improved anti-VRE activity and solubility. In a VRE-A neutropenic thigh infection mouse model, compound 17 significantly lowered the bacterial load by 3-4 orders of magnitude. This study sets the stage to develop next-generation GPAs in response to growing VRE infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gram-Positive Bacterial InfectionsVancomycin-Resistant EnterococciAnimalsMiceAnti-Bacterial AgentsGlycopeptidesMicrobial Sensitivity TestsSynthetic BiologyVancomycinIohexol

Substanzen

Anti-Bacterial AgentsGlycopeptidesVancomycincompound 17Iohexolrimomycin A

Autor:innen und Institutionen

  • David Braley Centre for Antibiotic Discovery, M.G. DeGroote Institute for Infectious Disease Research, Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario L8S 4K1, Canada.
  • Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, West 7th Avenue No. 32, 300308 Tianjin, China.
  • Haihe Laboratory of Synthetic Biology, West 15th Avenue No. 21, 300308 Tianjin, China.

ORCID-Profile: Michael A Cook, Gerard D Wright

Förderung

  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Koteva, K., Xu, M., Wang, W., Fiebig-Comyn, A. A., Cook, M. A., Coombes, B. K., & Wright, G. D. (2023). Synthetic Biology Facilitates Semisynthetic Development of Type V Glycopeptide Antibiotics Targeting Vancomycin-Resistant Enterococcus. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00633

Vancouver

Koteva K, Xu M, Wang W, Fiebig-Comyn AA, Cook MA, Coombes BK, et al. Synthetic Biology Facilitates Semisynthetic Development of Type V Glycopeptide Antibiotics Targeting Vancomycin-Resistant Enterococcus. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00633

BibTeX
@article{Koteva2023,
  author = {Koteva, Kalinka and Xu, Min and Wang, Wenliang and Fiebig-Comyn, Aline A and Cook, Michael A and Coombes, Brian K and Wright, Gerard D},
  title = {Synthetic Biology Facilitates Semisynthetic Development of Type V Glycopeptide Antibiotics Targeting Vancomycin-Resistant Enterococcus},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c00633}
}
Kostenlos starten →